Skip to content
10-Q

Quarterly Report

Lipella Pharmaceuticals Inc. LIPO

0001753926-25-000818

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 13, 2025 4.47M sh
Shares Diluted Q1 2025 · Mar 31, 2025 2.06M sh
Shares Diluted restated Q1 2025 · Mar 31, 2024 911.52K sh
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$1.43M
Operating Cash Flow restated Q1 2025 · Mar 31, 2024 −$1.39M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $4.23M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $2.18M
Stockholders Equity Q1 2025 · Mar 31, 2025 $4.08M
Stockholders Equity Q1 2025 · Dec 31, 2024 $1.92M
Stockholders Equity restated Q1 2025 · Mar 31, 2024 $2.56M
Stockholders Equity Q1 2025 · Dec 31, 2023 $3.14M
Current Liabilities Q1 2025 · Mar 31, 2025 $776.85K
Current Liabilities Q1 2025 · Dec 31, 2024 $754.42K
Total Liabilities Q1 2025 · Mar 31, 2025 $776.85K
Total Liabilities Q1 2025 · Dec 31, 2024 $754.42K
Current Assets Q1 2025 · Mar 31, 2025 $4.82M
Current Assets Q1 2025 · Dec 31, 2024 $2.62M
Total Assets Q1 2025 · Mar 31, 2025 $4.86M
Total Assets Q1 2025 · Dec 31, 2024 $2.67M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.64
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$1.31
Eps Basic Q1 2025 · Mar 31, 2025 −$0.64
Eps Basic restated Q1 2025 · Mar 31, 2024 −$1.31
Sga Expense Q1 2025 · Mar 31, 2025 $463.74K
Sga Expense Q1 2025 · Mar 31, 2024 $520.93K
Rd Expense Q1 2025 · Mar 31, 2025 $993.48K
Rd Expense Q1 2025 · Mar 31, 2024 $842.6K
Net Income Q1 2025 · Mar 31, 2025 −$1.31M
Net Income Q1 2025 · Mar 31, 2024 −$1.19M
Operating Income Q1 2025 · Mar 31, 2025 −$1.33M
Operating Income Q1 2025 · Mar 31, 2024 −$1.22M
Revenue Q1 2025 · Mar 31, 2025 $129.39K
Revenue Q1 2025 · Mar 31, 2024 $145.88K